Rotem Greenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rotem Greenberg has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Shay Ben-Shachar
Clalit Health Services 2 Innovation Division Clalit Research Institute, Ramat Gan, Israel
4 shared publications - Lina Basel-Vanagaite
Innovation Division, Maccabi Healthcare Services, Tel Aviv, Israel
2 shared publications - Noa Ruhrman-Shahar
The Raphael Recanati Genetics Institute, Rabin Medical Center—Beilinson Hospital, Petah Tikva 49100, Israel
2 shared publications Ofer Isakov
Clalit Research Institute, Clalit Health Services, Tel Aviv-Yafo, Israel
2 shared publications- Ofer Isakov
Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel; The Ivan and Francesca Berkowitz Family Living Laboratory, Harvard Medical School, Boston, Massachusetts, and Clalit Research Institute, Ramat Gan, Israel; Gray Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel
2 shared publications Samah Hayek
Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan
2 shared publications
Latest Publications
- 12 August 2026
- Published by BMJ in Journal of Medical Genetics
Pan-ethnic preconception screening: evidence from a large-scale programme in a genetically diverse population
Background Preconception genetic screening is a key preventive strategy for identifying at-risk couples (ARCs) of inherited disorders and supporting informed reproductive decision-making. However, increasing population admixture and the widespread adoption of next-generation sequencing challenge the validity of ancestry-driven risk stratification. Methods A total of 107 739 individuals participated in the national screening programme, including 51 722 couples and 4295 individuals tested independently, representing 33 ethnic groups. Under the sequential testing strategy, all women underwent initial screening, whereas male partners were tested only when a pathogenic variant (PV) was identified in the female partner. Consequently, carrier-status results were available for 76 317 individuals. Results Among 76 317 individuals tested, 30 475 (39.9%) carried at least one PV. ARCs were identified in 1.15% of couples, reaching up to 10% in certain ethnic groups. Risk increased with shared ancestry, rising to 5.72% among same-ancestry couples versus 1.28% among mixed-ancestry couples (OR 4.69; 95% CI 3.70 to 6.01). Compared with ethnicity-based screening, the pan-ethnic targeted common variant (TCV) screening approach identified 11.9% more ARCs, with 26.8% of variants detected outside their historically associated populations. Postimplementation analyses also identified variants with limited yield, supporting periodic panel refinement. Conclusion The TCV approach improves carrier and ARC detection compared with ethnicity-based approaches and represents a practical screening model for genetically diverse populations. These findings support consideration of the TCV approach as a practical screening strategy in genetically diverse populations, with continuous panel refinement, inclusive reference datasets and targeted outreach to high-risk communities essential to maximising its population impact.
- 12 August 2026
- Published by BMJ in Journal of Medical Genetics
Pan-ethnic preconception screening: evidence from a large-scale programme in a genetically diverse population
Background Preconception genetic screening is a key preventive strategy for identifying at-risk couples (ARCs) of inherited disorders and supporting informed reproductive decision-making. However, increasing population admixture and the widespread adoption of next-generation sequencing challenge the validity of ancestry-driven risk stratification. Methods A total of 107 739 individuals participated in the national screening programme, including 51 722 couples and 4295 individuals tested independently, representing 33 ethnic groups. Under the sequential testing strategy, all women underwent initial screening, whereas male partners were tested only when a pathogenic variant (PV) was identified in the female partner. Consequently, carrier-status results were available for 76 317 individuals. Results Among 76 317 individuals tested, 30 475 (39.9%) carried at least one PV. ARCs were identified in 1.15% of couples, reaching up to 10% in certain ethnic groups. Risk increased with shared ancestry, rising to 5.72% among same-ancestry couples versus 1.28% among mixed-ancestry couples (OR 4.69; 95% CI 3.70 to 6.01). Compared with ethnicity-based screening, the pan-ethnic targeted common variant (TCV) screening approach identified 11.9% more ARCs, with 26.8% of variants detected outside their historically associated populations. Postimplementation analyses also identified variants with limited yield, supporting periodic panel refinement. Conclusion The TCV approach improves carrier and ARC detection compared with ethnicity-based approaches and represents a practical screening model for genetically diverse populations. These findings support consideration of the TCV approach as a practical screening strategy in genetically diverse populations, with continuous panel refinement, inclusive reference datasets and targeted outreach to high-risk communities essential to maximising its population impact.
- Open Access
- 14 March 2026
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 36 (2)
Psychologically informed reminder messages for promoting BRCA1/2 carrier screening: evidence from a large-scale population-based study
Psychologically Informed Reminder Messages (PIRMs) may promote health-behavior change, but their impact on preventive genetic screening is unclear. Due to low adherence to a screening program, Clalit Health Services initiated an intervention to encourage BRCA1/2 carrier screening in July 2022. This observational study assesses the effectiveness of the intervention in encouraging screening and its spillover effect on related healthcare utilization, focusing on Ashkenazi Jewish females aged 25–50 with no relevant cancer history. Patients were randomly assigned to receive one of five PIRMs. Four PIRMs utilized different psychological strategies, while the fifth served as a control. The effectiveness of the intervention on screening adherence was assessed using a regression discontinuity analysis. A Cox regression assessed the effectiveness of the four PIRMs compared to the control. Spillover effects on healthcare utilization were evaluated using logistic regressions. The intervention showed a positive correlation with increased adherence to screening (β = 0.37, 95% CI: 0.01–0.72). The “Barrier Remover” PIRM emphasized ease (hazards ratio = 1.09, 95% CI: 1.02–1.16), while the “Health Control” PIRM focused on autonomy (hazards ratio = 1.07, 95% CI: 1.01–1.14), both indicating greater effectiveness than the control. The findings suggest a positive short-term spillover effect of the “Health Control” PIRM on healthcare utilization compared to the control (odds ratio = 1.16, 95% CI: 1.04–1.29). PIRMs effectively increased BRCA1/2 carrier screening adherence, demonstrating a scalable, low-cost intervention to improve preventive healthcare uptake. The effect varied by the psychological strategies, highlighting the potential of tailored behavioral interventions to enhance public health.
- 14 March 2026
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 36 (2)
Open AccessPsychologically informed reminder messages for promoting BRCA1/2 carrier screening: evidence from a large-scale population-based study
Psychologically Informed Reminder Messages (PIRMs) may promote health-behavior change, but their impact on preventive genetic screening is unclear. Due to low adherence to a screening program, Clalit Health Services initiated an intervention to encourage BRCA1/2 carrier screening in July 2022. This observational study assesses the effectiveness of the intervention in encouraging screening and its spillover effect on related healthcare utilization, focusing on Ashkenazi Jewish females aged 25–50 with no relevant cancer history. Patients were randomly assigned to receive one of five PIRMs. Four PIRMs utilized different psychological strategies, while the fifth served as a control. The effectiveness of the intervention on screening adherence was assessed using a regression discontinuity analysis. A Cox regression assessed the effectiveness of the four PIRMs compared to the control. Spillover effects on healthcare utilization were evaluated using logistic regressions. The intervention showed a positive correlation with increased adherence to screening (β = 0.37, 95% CI: 0.01–0.72). The “Barrier Remover” PIRM emphasized ease (hazards ratio = 1.09, 95% CI: 1.02–1.16), while the “Health Control” PIRM focused on autonomy (hazards ratio = 1.07, 95% CI: 1.01–1.14), both indicating greater effectiveness than the control. The findings suggest a positive short-term spillover effect of the “Health Control” PIRM on healthcare utilization compared to the control (odds ratio = 1.16, 95% CI: 1.04–1.29). PIRMs effectively increased BRCA1/2 carrier screening adherence, demonstrating a scalable, low-cost intervention to improve preventive healthcare uptake. The effect varied by the psychological strategies, highlighting the potential of tailored behavioral interventions to enhance public health.
- Open Access
- 29 September 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 314-323
N-terminal truncating variants in CACNB1 cause a new congenital muscular disorder
Excitation-contraction (EC) coupling is an essential process for skeletal muscle function. Pathogenic variants in different EC coupling components have previously been associated with various neuromuscular disorders. In this study we aimed to identify the genetic etiology of a muscular condition characterized by early-onset muscle weakness, elevated CK, ptosis and low body weight, which was observed in three individuals from two unrelated consanguineous families. Exome sequencing (ES) performed in multiple individuals of one family, and ES in combination with SNP array-based homozygosity mapping in the proband of the other family, revealed different homozygous loss-of-function variants in the second exon of CACNB1 in the affected individuals from each family. CACNB1 encodes the β1 subunit of the skeletal muscle dihydropyridine receptor (DHPR), a voltage-gated Ca 2+ channel with a major role in EC coupling. Molecular impact of the identified variants was assessed in LHCN-M2 human myoblasts. Long-read RNA sequencing in LHCN-M2 wild-type myotubes showed that in differentiated skeletal muscle cells virtually all CACNB1 transcript isoforms contain exon 2 and will therefore be affected by genetic variants in this exon. Pathogenicity of the identified CACNB1 variants was further validated by replicating one of them (c.85-1G>A) in LHCN-M2 cells using CRISPR-Cas9-mediated base-editing. Analysis of LHCN-M2 edited myotubes demonstrated that in addition to the loss of β1 subunits, these cells displayed severely reduced protein levels of α1S, the pore-forming subunit of DHPR. We conclude that pathogenic variants in CACNB1 cause a new congenital muscular disorder.
- 29 September 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 314-323
Open AccessN-terminal truncating variants in CACNB1 cause a new congenital muscular disorder
Excitation-contraction (EC) coupling is an essential process for skeletal muscle function. Pathogenic variants in different EC coupling components have previously been associated with various neuromuscular disorders. In this study we aimed to identify the genetic etiology of a muscular condition characterized by early-onset muscle weakness, elevated CK, ptosis and low body weight, which was observed in three individuals from two unrelated consanguineous families. Exome sequencing (ES) performed in multiple individuals of one family, and ES in combination with SNP array-based homozygosity mapping in the proband of the other family, revealed different homozygous loss-of-function variants in the second exon of CACNB1 in the affected individuals from each family. CACNB1 encodes the β1 subunit of the skeletal muscle dihydropyridine receptor (DHPR), a voltage-gated Ca 2+ channel with a major role in EC coupling. Molecular impact of the identified variants was assessed in LHCN-M2 human myoblasts. Long-read RNA sequencing in LHCN-M2 wild-type myotubes showed that in differentiated skeletal muscle cells virtually all CACNB1 transcript isoforms contain exon 2 and will therefore be affected by genetic variants in this exon. Pathogenicity of the identified CACNB1 variants was further validated by replicating one of them (c.85-1G>A) in LHCN-M2 cells using CRISPR-Cas9-mediated base-editing. Analysis of LHCN-M2 edited myotubes demonstrated that in addition to the loss of β1 subunits, these cells displayed severely reduced protein levels of α1S, the pore-forming subunit of DHPR. We conclude that pathogenic variants in CACNB1 cause a new congenital muscular disorder.
- 16 July 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (10) , 101530
Genetics first approach: Expanding the utility of genetic testing by nongeneticist physicians
- 16 July 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (10) , 101530
Genetics first approach: Expanding the utility of genetic testing by nongeneticist physicians
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (1) , e004864
Mono and Biallelic Variants in TRIM63 Are Frequently Associated With a Unique Form of Hypertrophic Cardiomyopathy
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (1) , e004864
Mono and Biallelic Variants in TRIM63 Are Frequently Associated With a Unique Form of Hypertrophic Cardiomyopathy
- Open Access
- 6 July 2023
- Published by Elsevier in Genetics in Medicine Open
- Vol. 1 (1) , 100824
Carrier screening program for BRCA1/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: An observational study
- 6 July 2023
- Published by Elsevier in Genetics in Medicine Open
- Vol. 1 (1) , 100824
Open AccessCarrier screening program for BRCA1/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: An observational study